Q&A with Obesity Society’s CEO as the field prepares for next-gen meds
The race to create the next best medication for obesity is well underway, and the incumbents are doing everything they can to shore up manufacturing, fight the compounders and develop their own...
View ArticleBiogen brings in medical chief as CFO plans retirement; MacroGenics CEO...
→ Michael McDonnell is retiring as CFO of Biogen on Feb. 28, and Chris Viehbacher’s crew has lined up chief accounting officer Robin Kramer as his replacement. Peer Review covered McDonnell’s
View ArticleEssa’s shares tank as it looks for options after abandoning prostate cancer drug
Essa Pharma is exploring “strategic options” as it ends work on its prostate cancer drug that failed a mid-stage test. The company's shares {$EPIX} nosedived by as much as 65% premarket Friday. In a...
View ArticleBaxter pulls IV products out of China to shift supply to the US
Baxter has “suspended commercial activities” of its intravenous products in China to ease supply issues in the US caused by Hurricane Helene, the company told Endpoints News. “The urgent need to...
View ArticleExclusive: Blood stem cell therapy maker Garuda gets new CEO, adds $47M
Garuda Therapeutics has replaced its top leader and reeled in about $47 million to continue funding its blood stem cell therapy work, Endpoints News has learned. The Cambridge, MA-based biotech...
View ArticleFDA removes hold on three CARsgen CAR-T trials; Ono passes on itolizumab
Plus, news about Kymera Therapeutics, Nanoscope, Eupraxia, Alpha Cognition and EyePoint: FDA's decision on CARsgen’s CAR-T therapies: The FDA on Thursday lifted a clinical hold on three of CARsgen...
View ArticleNovo Nordisk claims late-stage MASH victory, continuing GLP-1's expansion
A day after Madrigal Pharmaceuticals impressed investors, Novo Nordisk is looking to steal the spotlight. The Danish drugmaker reported Friday that semaglutide succeeded in a Phase 3 study of patients...
View ArticleHeritage and Apotex to pay $49.1M in price-fixing settlement
Generic drug manufacturers Heritage Pharmaceuticals and Apotex have agreed to pay $49.1 million to settle allegations from nearly all US states that the companies inflated and manipulated drug prices...
View ArticleMaven Clinic cuts 10% of workforce weeks after raising $125M
Maven Clinic laid off 60 people on Monday, Endpoints News has learned. The layoffs at the unicorn health tech startup represented about 10% of its workforce and happened across the organization,...
View ArticleBMS, J&J and AstraZeneca plea with appeals court to overturn drug price...
A panel of three judges on the US Court of Appeals for the Third Circuit didn't offer too many hints at which side it would take as it heard oral arguments on Wednesday from a ...
View ArticleHow RFK Jr. might influence the FDA; Pharma's Q3 highlights; AbbVie's latest...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleCinRx touts positive data from two obesity drug candidates
CinFina Pharma, a subsidiary of the hub-and-spoke biotech CinRx, shared early-stage data for two of its Janssen-licensed obesity candidates at this year’s ObesityWeek. CIN-110, a PYY analog, and...
View ArticleNovo adds to Wegovy’s cardio strength with hospital admissions analysis
SAN ANTONIO — Novo Nordisk’s wildly popular anti-obesity drug Wegovy helped heart disease patients end up in the hospital less often and stay there for shorter durations than those on placebo,...
View ArticleViking oral weight loss drug shows promising Phase 1 data
SAN ANTONIO — Viking Therapeutics' highly anticipated readout of its oral anti-obesity pill showed a placebo-adjusted weight loss of 6.8% after four weeks, sticking the biotech near the front of a...
View ArticleEuropean Commission marks Dec. 6 for Novo-Catalent deal decision
The European Commission has set Dec. 6 as its deadline to decide if Novo Holdings’ multi-billion-dollar acquisition of Catalent passes its antitrust review, according to a notification on its website. ...
View ArticleMASH drug developers chart path forward as more patients use GLP-1s
For years, drug developers working to treat an advanced form of fatty liver disease known as MASH were chasing wide-open terrain. There were no products on the market, millions of potential patients...
View Article'We play to win': AstraZeneca details first results for oral GLP-1 and...
SAN ANTONIO — Well behind Novo Nordisk and Eli Lilly in the obesity race, AstraZeneca came to this year's ObesityWeek with three assets in hand as it hopes to "move beyond short-term weight loss" and ...
View ArticleNovo, Ascendis to work on monthly GLP-1; KalVista makes a royalty deal
Plus, news about Disc Medicine, OSE Immunotherapeutics, CrossBridge Bio, Lomond Therapeutics, Relief Therapeutics and Renexxion: Novo Nordisk, Ascendis Pharma ink deal: The Danish drugmaker will pay up...
View ArticleBioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edge
BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to investigate the asset in combination with other modalities. During the German...
View ArticleFDA expands faster drug review pilot from supplemental to full applications
The FDA on Dec. 2 will open up an expedited review pilot program that's meant to speed therapies that substantially improve upon what's currently available for serious conditions to full marketing...
View ArticleBioNTech eases 2024 revenue outlook despite hefty Covid vaccine third-quarter...
Despite strong third-quarter revenues, BioNTech has softened its 2024 sales guidance in light of changes to Covid-19 vaccine uptake, pricing and seasonal variations. The company’s €1.2 billion ($1.3...
View ArticleRare disease biopharma companies weigh in on FDA's new innovation hub
AstraZeneca's Alexion, BridgeBio, BioMarin, Ultragenyx and others, including Sen. Bob Casey (D-PA), recently weighed in on the details of a new cross-cutting FDA collaboration hub focused on rare...
View ArticleThe election is Tuesday. What’s at stake for the pharma industry?
The biopharma industry has been a bipartisan political target in recent years. But in the 2024 presidential election, details are scarce around key issues that could impact drugmakers. Drug pricing has...
View ArticleFDA cites Mark Cuban's drug compounding center in Dallas with sterility,...
The FDA is raising sterility and other quality concerns with Mark Cuban's Cost Plus Drugs compounding facility in Dallas, following a nine-day inspection of the site in August and September. A
View Article